Market news

Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD). After 14 days, median reductions on the Adult ADHD Investigator Symptom Rating Scale were 14 points at a total daily dose of 20 mg and 19 points at 50 mg. Both […]

In September 2026, Alkermes plc reported positive topline results from a phase 1b proof-of-concept study of ALKS 7290, an investigational orexin 2 receptor agonist, which showed clinically meaningful, dose-dependent improvements in adult ADHD symptoms over 14 days with a generally well-tolerated safety profile. These data represent the first clinical evidence of an orexin receptor agonist’s effects in ADHD, potentially widening Alkermes’ orexin franchise beyond sleep disorders and other...

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.

Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.

Alkermes plc (NASDAQ:ALKS) shares gained 6. 5% on Monday after the company reported positive Phase 1b clinical trial results for ALKS 7290, an investigational treatment for adults with attention-deficit hyperactivity disorder (ADHD).

ALKS stock slid 7% to a June low as healthcare peers fell.

Detailed price information for Alkermes Plc (ALKS-Q) from The Globe and Mail including charting and trades.

Alkermes is upgraded to Buy on strong revenue growth, Lumryz momentum, and orexin pipeline upside in sleep/CNS. Click to get the latest ALKS outlook now.

The insider still has significant holdings in the company, signaling confidence.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DUBLIN, August 24, 2026--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,

Detailed price information for Repligen Corp (RGEN-Q) from The Globe and Mail including charting and trades.

It was reported on July 28 that Alkermes plc (NASDAQ:ALKS) sank 5% to $50.05 following its second-quarter 2026 financial report. Despite topping top-line consensus estimates with a 27% year-over-year revenue surge to $496.0 million, profit-taking took hold after a massive year-to-date rally. The second-quarter revenue growth was anchored by $411.7 million in proprietary net sales. […]

Highlighted on August 3, it was unveiled in an SEC filing that Snyderman, Director at Alkermes (NASDAQ:ALKS), executed a significant transaction involving the exercise of company stock options. What Happened: Snyderman,

Alkermes stock has delivered a strong 84.5% return over the past year, yet its broader valuation checks suggest the shares are not a straightforward bargain at current levels. The 84.5% one-year gain puts recent performance front and center, which naturally raises the question of how much optimism is already in the share price. Expectations around Alkermes' orexin pipeline can support higher earnings potential, while any setback in development or commercialization may weigh heavily on what...

Alkermes (NasdaqGS:ALKS) shares were in focus after the company reported its second quarter 2026 results on July 28, highlighting higher revenue alongside a significantly lower quarterly net income figure. See our latest analysis for Alkermes. Despite the weaker quarterly net income, Alkermes shares trade at US$48.99 after a recent pullback, with the 7 day share price return down 7.37% and the 30 day share price return down 5.28%. However, the 90 day share price return of 46.76% and 1 year...

Detailed price information for Alkermes Plc (ALKS-Q) from The Globe and Mail including charting and trades.

Moby summary of Alkermes plc's Q2 2026 earnings call

Alkermes' (ALKS) base business supported the company's Q2 beat, while its orexin pipeline serves as

Although the revenue and EPS for Alkermes (ALKS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Alkermes PLC (ALKS) reports significant sales growth and strategic advancements, while navigating potential market competition and profitability hurdles.

ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.

Alkermes (ALKS) reported break-even earnings for Q2 Tuesday, compared with earnings of $0.52 per sha

Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

DUBLIN, July 28, 2026--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentation, please visit the company’s investor relations website at https://investor.alkermes.com.

Alkermes (NASDAQ:ALKS) reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following the company’s acquisition of Avadel. The company also highlighted progress across its orexin develop

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.